The first two authors contributed equally to this work This study investigates whether KMUP-l improves hepatic ischemia-reperfusion (IIR) and hypoxic cell injury via inhibiting Nox2-and reactive oxygen species (ROS)-mediated pro-inflammation. Rats underwent ischemia by occlusion of the portal vein and hepatic artery for 45 minutes. Reperfusion was allowed for 4 h. Serum was used for analysis of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). DNA extracted from liver homogenate was analyzed by electrophoresis to observe the fragmentation. Lipid peroxidation (LPO) was evaluated by measuring thiobarbituric acid-reactive substances (TBARS). NO and ROS contents were measured using Griess reagent and 2'-7'-dichlorofluorescein, respectively. Proteins levels were visualized by Western blotting. Liver damage was observed under a microscope. Intravenous KMUP-l (0.25,0.5 and 1 mg/kg) reduced I1R-induced ALT and AST levels, DNA fragmentation, ROS and malondialdehyde (MDA) and restored the NO levels of IIR rats. KMUP-l protected the liver architecture from worsening of damage and focal sinusoid congestion, increased endothelium NO synthase (eNOS), guanosine 3', 5'cyclic monophosphate (cGMP), protein kinase G (PKG) and the B-cell lymphoma 2/Bcl-2-associated X protein (Bcl-2/Bax) ratio, attenuated phosphodiesterase 5A (PDE-5A) and cleaved caspase-3 expression in IIR-liver. In hypoxic HepG2 cells, KMUP-l increased cGMPIPKG, restored peroxisome proliferator-activated receptor-y (PPAR-y) and decreased matrix metalloproteinases-9 (MMP-9), Rho kinase II (ROCK II), hypoxiainducible factor-In (HIF-la) and vascular endothelium growth factor (VEGF). KMUP-l protects liver from I/R-injury and hypoxic hepatocytes from apoptosis-associated free radical generation and proinflammation by restoring/increasing NO/cGMP/PPAR-y, reducing ROSINox2 and inhibiting ROCKIII MMP-9.
We investigated whether preoperative KMUP-I (7-[2-[4-(2-Chlorophenyl) piperazinyl] ethyl]-1,3dimethylxanthine, Fig. IA ) protects the liver from ischemia/reperfusion (I/R)-and hypoxia-induced cell injury and whether the underlying mechanism of liver protection is via reduced Nox2/reactive oxygen species (ROS) and increased NO/guanosine 3', 5'cyclic monophosphate (cGMP). KMUP-I was shown to increase NO/cGMP and to inactivate Rho kinase II (ROCKlI) and phosphodiesterase 5A (PDE-5A) or cGMP breakdown in smooth muscles (1, 2) and in hypoxic H441 lung epithelial cells (3) , and to open Kt-channel in vascular system (4) . We investigated how I/R liver and hypoxic cell injury resulted from apoptotic signalling and was regulated by increased NOlcGMP. I/R-induced liver injury is a major cause of morbidity and mortality associated with liver transplantation. During major liver resections, Pringle's manoeuvre provides better vascular control but may result in I/R liver injury and ultimately lead to hepatic failure (5) .Acute I/R is characterized by ROS production and severe oxidative stress that results in degradation of membrane lipids and/or proteins, eventually leading to apoptosis (6) . Caspase inhibitors are known to reduce I/R-liver injury by reducing the serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (7) . Morphological and biochemical studies, including DNA laddering, showed that hepatocytes and sinusoidal endothelial cells (SECs) undergo apoptosis soon after reperfusion (8) . I/R initiate in vivo apoptosis in hepatocytes and SECs (9) . In both cell types, I/R activates caspases, specifically caspase-3, thus promoting apoptotic DNA fragmentation. Particularly, hypoxia causes release of cytochrome c from the mitochondria to activate caspase-3 via proteolytic processing.
KMUP-I has been shown to increase NO (1) (2) (3) . In this regard, hepatic NO is vital during I/R, because NO counteracts vasoconstriction and maintains liver blood flow and oxygenation (10) . cGMP was shown to upregulate Bcl-2 (9) . Inhibition of phosphodiesterase-5 (PDE-5) raises the intracellular cGMP level, which activates cytosolic cGMP-dependent protein kinase (PKG). Therefore, vasodilatory NO and accumulated cGMP/PKG by inhibition of PDE-5A optimizes the protective effect against I/R-induced liver damage, potentially inhibiting ROS production (II).
Endogenous peroxisome proliferator-activated receptors (PPARs) are bound and activated by a variety of lipophilic ligands. The PPARs are a family of nuclear hormone-binding proteins which participate in diverse functions as transcriptional regulators. PPAR-y has been implicated as a regulator of cellular inflammatory and ischemic responses. PPAR agonists may exert their antiinflammatory effects by negatively regulating the pro-inflammatory genes (12) . Reduction of hepatic PPAR-y in I/R can be related to lipolytic activity. In fact, expression of eNOS and PPAR-y in hepatocytes suppresses lipolytic activity (13) . Hypoxia, which partially contributes to I/R, elicits downregulation of PPAR-y. Therefore, treatment to inhibit I/R-induced hepatic apoptosis and ROS requires restoration of PPAR-y.
Matrix metalloproteinases (MMPs), including MMP-9, are involved in degradation of extracellular matrix and MMP-9 has induced proteolytic activity in I/R (14) . Inhibition ofMMPs is a promising strategy to prevent hepatic I/R injury and up-regulate PPAR-y (12) . MMP-9 and PPAR-y have been looked at as two biomarkers ofhepatic inflammation (14) . We are thus encouraged to search for a PPAR-y-enhancer that is capable ofincreasing eNOS, restoring PPAR-y and suppressing MMP-9 in the I/R-liver.
cGMP regulates some gene expression associated with proliferation and apoptosis (15) . How the cGMP pathway and pro-inflammatory signaling related to oxidative stress remain to be investigated. Therefore, this study aims to determine mechanisms of action ofKMUP-1 on I/R liver and hypoxic cell apoptosis, focusing on lipolytic PPAR-y, proteolytic MMP-9, anti-apoptotic PKG, oxidative stress biomarkers p67 protein (Nox2) and ROS.
MATERIALS AND METHODS

Animal care and preparation
Male Wistar rats weighing between 250 g and 300 g were used for the following experiments. Animals were provided by the National Laboratory Animal Breeding and Research Centre (Taipei, Taiwan). The rats were acclimatized for one week in the animal facility, in which temperature, humidity, and light cycle were controlled, and food and water were provided ad libitum. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Kaohsiung Medical University.
Cell culture in hypoxia
The Hep G2 hepatoma cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco's modified Eagle medium. Culture media was supplemented with 10% heat-inactivatedFBS, penicillin (100 U/mL) and streptomycin (100 ug/ml.). Cells were grown in a humidified atmosphere containing 5% CO 2 at 37°C for 24 h. The oxygen tension was held at either 140 mm Hg (20% 02' v/v; normoxic condition) or 7 mm Hg (1% 02' v/v; hypoxic condition). Cell culture in hypoxic conditions was completed following 6 h hypoxia for PPAR-y, 6 and 24 h hypoxia for ROS, 24 h hypoxia for MMP-9 and 6 to 48 h hypoxia for Nox2 measurements. MMP-9 was not early expressed at 6 h.
Experimental design and pretreatmentfor fiR liver
Thirty male Wistar rats weighing 200-250 g were randomly divided into five groups (n=6): i) sham-operated; ii) I/R with vehicle; iii) I/R with KMUP-l (0.25 mg/kg); iv) I/R with KMUP-l (0.5 mg/kg); v) I/R with KMUP-l (1 mg/kg). Rats were anesthetized with sodium pentobarbital (40 mg/kg, i.p.) and then treated by bolus injection via the femoral vein (i.v.) 10 minutes before partial ischemia. All animals fasted for 12 h before the experiments but were allowed free access to water and underwent normothermic ischemic surgery by selective occlusion of the portal vein and hepatic artery for 45 min. Reperfusion was then allowed for 4 h. In sham-operated animals, the portal vein and hepatic artery were exposed without occlusion ( Fig.  lB) .
Blood, serum and liver sample preparation
At the end ofthe reperfusion, 5 ml ofblood was collected by heart puncture and placed in serum biochemical tubes. Blood samples were centrifuged at 3,000 rpm for 15 min at 4°C to isolate serum for biochemical analysis. Hepatic damage was evaluated by measuring concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). TheAST andALT determinations were performed using a Roche Modular system with a commercially available colorimetric enzymatic assay kit (Roche, Switzerland). Livers were rapidly removed in a cold room and processed for histopathological studies or biochemical analysis.
DNA fragmentation
Genomic DNA was isolated from liver homogenate with a Tissue and Cell Genomic DNA Purification kit (Genelvlark") according to the manufacturer's instructions.
The genomic DNA was subjected to gel electrophoresis on a 2% agarose gel and stained with ethidium bromide. The gel was then photographed under ultraviolet luminescence. In these conditions, damaged DNA appears as a ladder consisting of DNA fragments, whereas intact DNA has a high molecular weight and does not migrate very far into the gel.
Lipidperoxidation (LPO) assay
LPO was evaluated by measuring thiobarbituric acid-reactive substances (TBARS). Tissue lysates were prepared by suspending 0.5 g of wet tissue in 4.5 ml of 1.15% KCl. The tissue was then homogenised using a Teflon homogeniser until complete lysis was achieved. For the LPO assay, 40 ul oflO% (w/v) tissue homogenate was added to 40~l of8.l % SDS, 300~l of20% acetic acid solution, and 300~l of0.8% aqueous solution ofTBA. The mixture was made up to 800 ul by the addition of distilled water, and then heated at 95°C for 1 h. After cooling with ice water, 1.0 ml ofn-butanol was added, and the mixture was shaken vigorously, and centrifuged at 10,000 rpm for 10 min. The absorbance of the resulting supernatant was measured at 532 nm and 1,1,1,3-tetraethoxypropane (TEP) was used as the standard. The results were expressed as percent increments with respect to sham.
ROS ofI/R liver and hypoxic cells
ROS content was measured using 2'-7'-dichlorofluorescein (H2DCF-DA, Molecular Probe, USA). Briefly, 10 ul of liver homogenate was diluted 100-fold with cold PBS and labelled with 5 umol/L 2'-7'-dichlorofluorescein, and the mixture was incubated at 37°C for 30 minutes. Fluorescence was measured at 485 nm excitation and 530 nm emission to determine the concentration of HP2 (FLUOstar Galaxy, Germany). HepG2 cells were incubated with 5 umol/L 2'-7'-dichlorofluorescein for 30 min following 6 and 24 h hypoxia in the presence of vehicle or KMUP-l (10, 100 mM). Resulted ROS was determined by a Flow Cytometer (Beckman Coulter, USA).
Hepatic nitrate/nitrite
Liver tissue was homogenised in 9 volumes of cold PBS and centrifuged at 10,000 rpm for 30 min. Samples (100 ul) or serial dilutions of the NaN0 2 standard (linear range 0-100~M) were aliquoted into a microtiter plate well. The total nitrite in each sample was determined by adding 50 ul Griess reagent 1 (1% sulfanilamide in IN HCl) followed by Griess reagent 2 (0.1% N-(1napthylj-ethylenediamine), The mixture was incubated for 10 min in the dark. Optical density was measured spectrophotometrically at 540 nm. Nitrate/nitrite levels were expressed as percent increments inrespect to sham.
Western blotting
Liver tissues were homogenised in lysis buffer (Pierce, USA). After 15 min on ice and centrifugation (13,000 rpm, 30 min, 4°q, supernatants were snap frozen, and aliquots were stored at -80°C. The protein concentration was determined using the Bio-Rad protein assay kit. The hepatic protein levels were detected by immunoblotting with antibodies against eNOS, PDE-5, PKG, Bcl-2, Bax, and cleaved Caspase-3. Briefly, aliquots of homogenate containing 30 ug of protein were separated by SDS-PAGE and transferred to a PVDF membrane. To block nonspecific binding sites, the membranes were incubated overnight with 5% non-fat dry milk in 10 mM Tris-HCl (pH 7.4)-150 mM NaCI-0.05% Tween 20 (TBST) buffer at 4°C. After washing with TBST, the membranes were incubated in diluted primary antibody overnight at 4°C with constant shaking. The membranes were then washed and probed with horseradish peroxidase-conjugated antimouse or anti-rabbit IgG. Chemiluminescence detection was performed using an enhanced chemiluminescence detection kit (Abeam, Cambridge, UK), according to the manufacturer's instructions.
Histopathology and immunohistochemistry
Liver tissue was fixed in 10% buffered formalin for 24 h and then embedded in paraffin. Four micron sections were stained with hematoxylin and eosin. The paraffin-embedded liver sections (4 urn thick) were first heat immobilised and deparaffinised using xylene and then rehydrated in a graded series of ethanol, followed by a final wash in distilled water. Antigen retrieval was performed in Dako target retrieval solution (pH 9.0) in a vegetable steamer followed by quenching of endogenous peroxidase activity with 3.0% HP2 in methanol. Sections were then incubated with specific primary antibodies overnight at 4°in a humidified chamber. The antibodies used included rabbit polyclonal anti-eNOS (1:50 dilution) (Abeam, Cambridge, UK) or rabbit monoclonal anticleaved caspase-3 (1:50 dilution) (Cell Signaling, USA). The sections were then examined using a DAKO REAL Envision" Detection System kit (DAKO, Carpinteria, CA, USA) and counterstained with haematoxylin. Images were obtained through a Nikon Eclipse TE200-S microscope.
Statistical analysis
All data are expressed as mean ± standard error of the mean (SEM). An unpaired Student's r-test or one-way analysis of variance (ANOVA) followed by Dunnett's test were performed to estimate significant differences among groups. The differences between groups were considered to be significant at p:::::0.05. Statistical analysis was conducted using GraphPad InStat version 3.0a for the Macintosh (GraphPad Software, San Diego, CA, USA).
RESULTS
Serum AST and ALT
Untreated IIR-rats had a significant increase in serum ALT and AST activities compared with sham-operated rats. Treatment with KMUP-l dosedependently reduced serum ALT and AST activity in IIR rats (Fig. 1C, D) .
Histopathology
The livers of sham-operated rats had normal hepatic architecture; in contrast, the IIR-untreated rats (vehicle group) showed hepatic sinusoid congestion, hepatocyte necrosis, and neutrophil infiltration (Fig.  IE) . The lobes of IIR rats treated with KMUP-I (0.25 mg, 0.5 mg and 1 mg/kg) demonstrated intact hepatic architecture and focal sinusoid congestion, and appeared similar to those of the sham-operated rats.
ROS and malondialdehyde (MDA) and hepatic apoptotic signalling
ROS plays an important role in various hepatic pathologies such as IIR injury and is known to promote widespread alterations in LPO. MDA is an index of LPO. Our data demonstrated significant elevations of hepatic ROS and MDA in untreated IIR-rats compared to sham-operated animals, whereas pre-treatments with KMUP-I were more efficient than vehicle treatment for reducing ROS and MDA levels of I/R-rats ( Fig. 2A, B ). KMUP-l dose-dependently decreased caspase-3 and increased the Bcl2/Bax ratio, indicating anti-apoptotic activity (Fig. 2C, D) .
DNA fragmentation
Apoptosis was assessed by DNA fragmentation. Compared to sham-operated rats, our results show that ischemia resulted in marked DNA laddering in vehicle group, and KMUP-l dose-dependently decreased the DNA laddering caused by I/R (Fig. 3A) . lining cells. In the vehicle group, only a portion of sinusoidal endothelial cells were stained and the staining intensity was decreased. In contrast, KMUP-1 dose-dependently restored the liver from I/Rinduced eNOS rarefaction (Fig. 3B ). The cleavage of caspase-3 causes activation of the protein and the presence of cleaved caspase-3 indicates that cells are undergoing apoptosis. The data show that caspase-3 (brown color) was significantly activated in the vehicle group. In contrast, there was a significant decrease of activated caspase-3 after KMUP-l in the IIR-treated groups (Fig. 3C ).
Hepatic nitrate/nitrite, eNOS, PDE-5A and PKG expression
The Griess reagent assay was used to measure the levels of NO, represented by nitrate/nitrite, in hepatic homogenate fluids as described previously (2) . There was a significant decrease in NO levels in the vehicle group after IIR. In contrast, the level of NO in hepatic fluids was significantly enhanced by the administration of KMUP-l (Fig. 4A ). The expression of eNOS and PKG was decreased by IIR, respectively, compared with sham-operated rats. In contrast, KMUP-I administration dose-dependently reversed this phenomenon in I/R-rats (Fig. 4B, D) . PDE-5A expression was significantly enhanced in I1R-treated rats compared with sham-operated rats (Fig.4C ).
HIF-Ia and VEGF in Hypoxic HepG2 cells
KMUP-I reduced both HIF-Ia and VEGF protein expression in a concentration-dependent manner under hypoxic conditions for 24 h (Fig. 5A, B ).
( Fig. 6A, B ) and decreased ROCKII/MMP-9 ( Fig.  6C, D) in normoxia or hypoxia, respectively. Fig. 7A showed that hypoxia decreased cellular PPAR-y and pretreatment with KMUP-I (O.I~lO mM) concentration-dependently restored PPAR-y to near normal levels in HepG2 cells. However, hepatic eNOS was increased concentrationdependently in normoxia at 6 h ( Fig. 7B ). induced increases of hepatic Nox2 from 6 to 24 h but not at~48 h. Fig. 7D showed that KMUP-I decreased ROS production at 6 and 24 h. expression of ROS/Nox2. eNOS-PDE-5A1PKG and PPAR-y-MMP-9-ROCKII-Nox2 were examined as therapeutic targets for treatment.
Restoration of PPAR-y and increase of eNOS in HepG2 cells
DISCUSSION
Hepatic I/R has significant effects on apoptosis regulated by mitochondrial permeability transition releasing cytochrome c, MMPs and VEGF. Hypoxia initiates caspase activation and mitochondrial cytochrome c release, leading to apoptosis of cells (16) . KMUP-l was suggested to protect IfR.liver and hypoxic cells from the oxidative damage induced by
Morphologic liver damage and apoptotic signaling
Based on morphological assessment, we found evidence of tissue damage, including congestion, necrosis and inflammation, following I/R. In apoptotic signaling
LPO, ROS and NO
The acute phase of I/R is characterized by the activation of liver cells, including Kupffer and other hepatic cells, resulting in production of ROS, which generates oxidative splices of tissue by virtue of its ability to degrade membrane lipids and/or proteins (17) . In HepG2 cells, KMUP-l protects cells from hypoxia-induced ROS production. ROS may cause hepatic cell damage by LPO and protein oxidation, evidenced by DNA fragmentation following I1R. On the other hand, LPO is an indicator ofROS formation and the increased ROS contributes to LPO, which is the cause of cell death (18) . NO release by KMUP-l may protect tissue by virtue of its ability to induce vasodilation, counteracting vasoconstriction via I/R and maintaining the liver blood flow and oxygenation (10) .
ASTIALT and MMP-9
In liver transplant patients, the postoperative level of AST correlates with the serum level of MMP-9 (18) . Inhibition of MMP activity significantly decreased liver injury in post-ischemic liver tissue, as assessed by histological studies and serum hepatic enzyme levels. We analysed the impact of KMUP-l on MMP-9 in hepatocellular necrotic/apoptotic IIR injury during initial reperfusion for 240 min. Our data demonstrate that KMUP-l inhibited MMP-9 in hypoxic cells and reduced AST and ALT activity in serum, suggesting a protective effect against I/R. hypoxia-induced ROCKII in HepG2 cells; therefore, there is a cGMP/PKG-dependent inhibition pathway for ROCKII.
NO/c GMP and ROeKJI
KMUP-I has demonstrated vascular inhibition again st a U46619-induced increase of PDE-5A (1). Acti vation of eNOS , which is found in SECs , can relea se NO , causing hepatic vasodilation. NO is involved in cardioprotection durin g reoxygenation (18) . Inhibition of PDE-5A raises intracellular cGMP, activating cytosoli c cGMP-dependent PKG . KMUP-I reduced I/R-induced PDE-5A and increased the expression of PKG in liver, protecting against IIR-induced apoptosis. KMUP-I inhibited
Proteolytic and inflammatory MMP -9
IIR injury remain the primary reason for hepatic dysfunction after transplantation and major resection. Inhibition of MMPs is an appealing and promi sing strategy for pharmacological intervention in post-ischemic hepatic damage. MMPs, which are expressed in endothelial cells, Kupffer cells and various subsets of inflammatory leukocytes, are critically involved in the degradation of the extracellular matri x. KMUP-l inhibits the expre ssion of MMP-9 in hypoxic HepG2 cells, indicating that KMUP-l prevents the inflammatory progression of I1R in vivo.
Activation ofPPAR-y by KMUP-l might limit the expression of MMP-9, and could be therapeutically applicable in anti-inflammatoryprocesses for reducing I/R liver injury, although KMUP-l might partly inhibit MMP-9 by nitration through the peroxynitrate produced by increased NO. This question remains to be examined. ROS has been implicated in MMP-9 upregulation/activation (18) . ROS, which leads to LPO in I/R liver, is suggested to increase MMP-9; treatment with KMUP-l potentially inhibits expression of proteolytic MMP-9 caused by ROS (8) .
HIF-laJVEGFIROCKIIIMMP-9
HIF-la and VEGF "are biomarkers of hypoxic cell signalling. Inhibition of VEGF plays an important anti-inflammatory role. Proteolytic MMP-9 is overexpressed during I1R and hypoxic injury (19) . KMUP-l inhibits VEGF and MMP-9 signalling, thereby reducing inflammation during I1R and hypoxia-induced injury. Hypoxia stimulates VEGF, which can activate the PI3KlRho/ROCK and c-Myc pathways. The downstream target gene of these pathways is MMP-9. The ROCK inhibitor Y-27632 has been shown to disrupt VEGF-mediated regenerative angiogenesis (20) . Thus, KMUP-l inhibits hypoxia-induced HIF-laIR.OCKII, VEGF and MMP-9, which could not be expressed in shortterm I1R liver within 4 h after vascular occlusion.
Anti-inflammatory PPAR-y
PPAR-y has been recognised as a regulator of inflammation. Reduced PPAR-y expression is associated with inflammatory signalling involving cell membrane degradation mediated by a lipolytic pathway. Inhibition of PPAR-y contributes to metabolic inflammation disorders. A PPAR-y agonist suppresses IL-6-stimulated lipolysis and increased PPAR-y signalling prevents nuclear factor-KB (NFKB) activation (21) . KMUP-l restores the hypoxia-induced reduction of PPAR-y, indicating that it acts as a PPAR modulator to protect from I/Rinduced liver injury.
eNOSIROCKIIIPPAR-y
cGMP generated by activation of sGC has been shown to protect against I/R injury (11). KMUP-l enhances eNOS/PKG and reduced I1R-inducedPDE-SA, enabling increasing blood flow and protecting against I/R-induced injury and apoptosis. PPAR agonists have attenuated endothelial dysfunction (22) . The PPAR-y/eNOS pathway improves endothelial function and has displayed cardioprotective effects; eNOS and ROCKII expression have an inverse relationship in the cardiovascular system as well as in the I/R liver (23) . PPAR-y has been shown to be a downstream target of ROCK in liver cells; inhibition of ROCK was demonstrated to increase PPAR-y (24) . In addition, ROCK inhibitor inhibited vascular wall apoptosis and extracellular matrix proteolysis (25) . In hypoxic HepG2 cells, KMUP-l could inhibit RhoA/ROCKII signalling to restore PPAR-y at 6 h of I1R before MMP-9 expression at 24 h, potentially preventing from cell apoptosis.
NOlcGMP and anti-apoptosis
Bcl-2 is an apoptosis inhibitor and Bax is a member of the Bcl-2 family that accelerates apoptosis when it is overexpressed. Bax can be activated by NO released from SECs and cytochrome c released from the mitochondria (11). I1Rincreases cleavage of caspase-3 and decreases the Bcl-2/Bax ratio (26) . NO-mediated activation of PKG via the sGC/cGMP pathway opens mitochondrial KArp channels, thereby reducing calcium accumulation and preventing loss of cytochrome c from the intermembrane space (27) .
NOlcGMP and oxidative stress marker Nox21ROS
Hepatic I/R may result in endothelial cell activation, up-regulation of adhesion molecules, inflammatory mediator TNF-a and cytokine release, and leukocyte accumulation, resulting in sinusoid contraction, blood sedimentation, hypoxia and further release of inflammatory mediators (6) . KMUP-l was demonstrated to deliver NO and increase cGMP by inhibition of PDE-5A, producing synergistic therapeutic benefits in I/R-liver injury by preventing ROS production (15) . In HepG2 cells, Nox2 was increased by hypoxia from 6 to 24 h, time-dependently. KMUP-l could not inhibit hypoxia-induced Nox2 at 2:48 h. Hypoxia-induced oxidative stress can initiate cell apoptosis by invasion on cell membrane and also mitochondria. KMUP-l can inhibit ROS production in hypoxia and also in IIR liver.
Protection from fiR liver injury and hypoxic cell apoptosis
Hypoxia induces mitochondrial dysfunction in inflammatory disease, driving mitochondrial genome mutagenesis, and antioxidants significantly rescue these events besides oxidative stress from cell membrane (28) . In this study, Nox2, eNOS and PPAR-y almost significantly express at 6 h after hypoxia. As evidenced by its inhibition of ROS production, KMUP-l protects hepatocytes from I/R injury and hypoxic cell apoptosis via Nox2 and ROS.
Anti-oxidant activity
Oxidative stress, such as increased levels ofROS, has been suggested as a pathomechanism of different diseases. Nox inhibitors have been re-interpreted as a direct antioxidant to inhibit high ROS-associated diseases such as I/R-induced cell apoptosis and liver injury (29) . eNOS enhancer or endogenous NO donor KMUP-l might function as a potent antioxidant eNOS activator for the treatment of ROSinduced IIR liver injury and hypoxic cell apoptosis.
Time limitation offiR
Pringle's manoeuvre during liver surgery is usually completed within a very short time. Longer hepatic I/R duration may cause serious necrosis (30) . All the parameters ofI/R by portal vascular occlusion for 45 min expose the co-expressed proteins before significant necrosis. Increased hepatic VEGF, HIFla and MMP-9 require a longer duration of IIR. We analysed hepatocellular necrotic/apoptotic IIR injury during the initial reperfusion of liver for 4 h. Hypoxic HepG2 cell culture for 6 or 24 h was able to be measured the changes in protein expression. Oxidative stress, including stress caused by I/R and hypoxia, induces liver injury and cell apoptosis via Nox2 and ROS production as illustrated in Fig. 8 . KMUP-l, a xanthine-based anti-oxidant compound, protects liver from IIR injury by increasing vasodilatory NO and cGMP/PKG. In hypoxic HepG2 cells, KMUP-I displays restoration of PPAR-y and inhibition of MMP-9 via decreasing ROS/Nox2 and associated LPO. KMUP-l acts as an-antioxidant eNOS activator, endogenous NO donor and K+channel opener (1) (2) (3) (4) . These merits are beneficial for liver injury caused by oxidative damage during hepatic surgery and hypoxic apoptosis associated with free radical generation. KMUP-I has similar elevated anti-proinflammatory benefits in liver as in lung tissue (1-2). In conclusion, increased eNOS by KMUP-I, acting as an anti-oxidant, protects liver from oxidative stress via Nox2-IROS-induced cell apoptosis and pro-inflammation.
